| Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912) |
|---|
| 09/27/2007 | US20070224294 Novel non-surgical method for treating cataracts in mammals including man |
| 09/27/2007 | US20070224292 Extended effect ergogenic drink |
| 09/27/2007 | US20070224291 Cancer treatment |
| 09/27/2007 | US20070224290 Nutrient supplements and methods for treating autism and for preventing the onset of autism |
| 09/27/2007 | US20070224287 Methods of Modulating Inflammatory Reactions by Modulating Xanthine Oxidoreductase Activity |
| 09/27/2007 | US20070224284 Methods and compositions comprising at least one alpha3 beta4 nAChR antagonist or pharmaceutically acceptable salt thereof |
| 09/27/2007 | US20070224283 Pharmaceutical compositions comprising crosslinked amine polymer with repeat units derived from polymerization of tertiary amines |
| 09/27/2007 | US20070224280 Novel nanoparticles for delivery of active agents |
| 09/27/2007 | US20070224279 Stabilization of chemical compounds using nanoparticulate formulations |
| 09/27/2007 | US20070224278 Triamcinolone composition; injected into eye; stability; mixture of corticosteroid particles and sodium hyaluronate in aqueous carrier |
| 09/27/2007 | US20070224277 Hyaluronic acid-based cross-linked nanoparticles |
| 09/27/2007 | US20070224275 Selenium-based biocidal formulations and methods of use thereof |
| 09/27/2007 | US20070224272 Method and composition for burned skin |
| 09/27/2007 | US20070224271 Healing powder and method of use thereof |
| 09/27/2007 | US20070224270 Nicotinic Acid Compositions For Treating Hyperlipidemia and Related Methods Therefor |
| 09/27/2007 | US20070224268 Process for preparing oral calcium compositions |
| 09/27/2007 | US20070224267 Ambroxol for the treatment of painful conditions in the mouth and pharyngeal cavity |
| 09/27/2007 | US20070224266 Descarbonylethoxyloratadine containing pharmaceutical composition |
| 09/27/2007 | US20070224265 Tablet Comprising Branched Chain Amino Acid and Method for Producing the Same |
| 09/27/2007 | US20070224263 Aminoalkylphosphonates and related compounds as Edg receptor agonists |
| 09/27/2007 | US20070224262 Solid Dosage Form of Wetted Heparin |
| 09/27/2007 | US20070224259 Anti-inflammatory pharmaceutical composition |
| 09/27/2007 | US20070224253 Transdermal Delivery of Meptazinol |
| 09/27/2007 | US20070224250 Mold-resistant construction materials |
| 09/27/2007 | US20070224246 Biocompatible intraocular implants, such as microparticles, include a prostamide component and a biodegradable polymer that is effective in facilitating release of the prostamide component into an eye for an extended period of time. The prostamide component may be associated with a biodegradable polymer |
| 09/27/2007 | US20070224243 Medical Devices And Methods Of Making Medical Devices |
| 09/27/2007 | US20070224231 Anti Acne Skincare Composition and Skincare Article |
| 09/27/2007 | US20070224226 Composition and method of use thereof |
| 09/27/2007 | US20070224213 Pharmaceutical Composition Comprising an Extract or Compounds Isolated from Elfvingia Applanata for the Prevention and the Treatment of Diabetes and Diabetic Complications |
| 09/27/2007 | US20070224210 Immunostimulatory nucleic acids |
| 09/27/2007 | US20070224207 Reagents and methods for cancer treatment and prevention |
| 09/27/2007 | US20070224204 Combination therapy of respiratory diseases using antibodies and anti-inflammatory agents |
| 09/27/2007 | US20070224200 Gm3 Synthase as a Therapeutic Target in Microvascular Complications of Diabetes |
| 09/27/2007 | US20070224198 Antithrombotic agents |
| 09/27/2007 | US20070224197 Three-dimensional structure of complement receptor type 2 and uses thereof |
| 09/27/2007 | US20070224196 Immunogenicity-reduced anti-cr1 antibody and compositions and methods of treatment based thereon |
| 09/27/2007 | US20070224194 Methods for Inhibiting Angiogenesis and/or Lymphangiogenesis |
| 09/27/2007 | US20070224178 Multimeric constructs |
| 09/27/2007 | US20070224173 Nonexpansion Protocol for Autologous Cell-Based Therapies |
| 09/27/2007 | US20070224167 Novel HCV inhibitor combinations and methods |
| 09/27/2007 | US20070224164 Degradable nanogel for drug delivery |
| 09/27/2007 | US20070224163 Absorbable alpha- cyanoacrylate compositions |
| 09/27/2007 | US20070224162 Antimicrobial releasing polymers |
| 09/27/2007 | US20070224161 Compositions and methods for making and using acyclic N-halamine-based biocidal polymeric materials and articles |
| 09/27/2007 | US20070224160 Nonleachable Composition and Method to Use |
| 09/27/2007 | US20070224159 Ophthalmic Compositions Containing A Synergistic Combination Of Three Polymers |
| 09/27/2007 | US20070224158 Method for the Cosmetic Treatment of Wrinkled Skin Using a Cosmetic Composition Containing a Tightening Agent and a Dispersion of Solid Particles of a Grafted Acrylic polymer |
| 09/27/2007 | US20070224153 High-deposition compositions and uses thereof |
| 09/27/2007 | US20070224152 Hair cleansing composition |
| 09/27/2007 | US20070224148 Beta-(1,3)-Beta-(1,4)-Glucan as Carrier for Chemical Substances |
| 09/27/2007 | US20070224135 Stable aqueous suspension concentrate for delivery of UV-labile water-insoluble biocides |
| 09/27/2007 | US20070224131 Pet chew article |
| 09/27/2007 | US20070224130 Tetrahydro-Naphthalene Derivatives as Glucocorticoid Receptor Modulators |
| 09/27/2007 | US20070224123 Proteins expressed by mycobacterium tuberculosis and not by bcg and their use as diagnostic reagents and vaccines |
| 09/27/2007 | US20070224122 Method of in vitro diagnosis which discriminates between exposure of a subject to Mycobacterium tuberculosis and vaccination with Bacille Calmette Guerin strain of Mycobacterium bovis, method comprising testing for presence of CD4 T lymphocytes that respond to MTBN4 |
| 09/27/2007 | US20070224116 Medical devices comprising a porous metal oxide or metal material and a polymer coating for delivering therapeutic agents |
| 09/27/2007 | DE60125416T2 Stabilisierte formulierungen von 6-hydroxy-3-(4-(2-(piperidin-1-yl)ethoxy)phenoxy)-2-(4-methoxyphenyl)benzo(b)thiophen und deren salze Stabilized formulations of 6-hydroxy-3- (4- (2- (piperidin-1-yl) ethoxy) phenoxy) -2- (4-methoxyphenyl) benzo (b) thiophene and their salts |
| 09/27/2007 | DE102006014543A1 Funktionelle Lebensmittel gegen Tumore Functional foods against tumors |
| 09/27/2007 | DE102006014324A1 Inhibitoren der löslichen Adenylatzklase Inhibitors of soluble Adenylatzklase |
| 09/27/2007 | DE102006014320A1 Inhibitoren der löslichen Adenylatzklase Inhibitors of soluble Adenylatzklase |
| 09/27/2007 | DE102006014319A1 Inhibitoren der löslichen Adenylatzyklase Inhibitors of soluble adenylate cyclase |
| 09/27/2007 | DE102006014165A1 Neue Isooxazol-Derivate und deren Verwendungen New isoxazole derivatives and uses thereof |
| 09/27/2007 | DE102006013914A1 Neue 7,12-Dihydro-7,12-dioxo-benz[a]anthracene, deren Herstellung und deren Verwendung als Arzneimittel New 7,12-dihydro-7,12-dioxo-benz [a] anthracene, their preparation and their use as medicaments |
| 09/27/2007 | DE102006013594A1 Quervernetzte Gele von Hyaluronsäure und deren Verwendung Cross-linked gels of hyaluronic acid and their use |
| 09/27/2007 | DE102006012876A1 Mittel zur positiven Beeinflussung der Alzheimer Krankheit und/oder zur Alzheimerprophylaxe Means for positively influencing Alzheimer's disease and / or Alzheimer's prevention |
| 09/27/2007 | DE102006012875A1 Agent, useful e.g. for effective inhibition of platelet aggregation, comprises very long-chain fatty acid based on guerbet acid and/or crude montana wax or corresponding component of raw carnauba wax or shellack |
| 09/27/2007 | DE102006012873A1 Agent, useful e.g. for the effective lowering of increased cholesterol levels in the blood, comprises long-chain carboxylic acid based on montana wax and their derivative and/or guerbet wax or the corresponding components of carnauba wax |
| 09/27/2007 | DE102006012872A1 Agent, useful e.g. for the effective lowering of increased cholesterol levels in blood, comprises long-chain carboxylic acid on the basis of montana waxes and/or guerbet acid or the corresponding components of carnauba wax or shellack |
| 09/27/2007 | DE102006012871A1 Agent, useful e.g. to lower increased cholesterol levels in blood, comprises long-chain wax esters based on montana wax or its derivative and/or guerbet derivative or carnauba wax in combination with nicotinic acid |
| 09/27/2007 | DE102006012671A1 Mittel zur Beeinflussung der Nozizeption und deren Folgen Means for influencing the nociception and its consequences |
| 09/27/2007 | DE102006012617A1 4-(Pyrrolopyridinyl)-pyrimidinyl-2-amin-derivate 4- (pyrrolopyridinyl) -pyrimidinyl-2-amine derivatives |
| 09/27/2007 | DE102006012545A1 Substituierte 2-Amino-4-phenyl-dihydrochinoline, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament, sowie sie enthaltendes Medikament Substituted 2-amino-4-phenyl-dihydroquinolines, processes for their preparation, their use as a medicament, and medicament containing them |
| 09/27/2007 | DE102006012544A1 Substituierte 1-Amino 4-phenyl-dihydroisochinoline, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament, sowie sie enthaltendes Medikament Substituted 1-amino 4-phenyl-dihydroisoquinolines, processes for their preparation, their use as a medicament, and medicament containing them |
| 09/27/2007 | DE102006010642A1 Arzneimittelformulierungen, enthaltend Fluorchinolone Pharmaceutical formulations containing fluoroquinolones |
| 09/27/2007 | CA2849661A1 Method of preventing and treating hepatic disease using a2b adenosine receptor antagonists |
| 09/27/2007 | CA2648829A1 Crystalline forms of n-{2-tert-butyl-1-[(4,4-difluorocyclohexyl)methyl]-1h-benzimidazol-5-yl}ethanesulfonamide salts |
| 09/27/2007 | CA2648785A1 Antibacterial agents |
| 09/27/2007 | CA2647769A1 Control of intracellular target molecule by ip3 receptor-binding protein |
| 09/27/2007 | CA2647297A1 Anti-cancer activity augmentation compounds and formulations and methods of use thereof |
| 09/27/2007 | CA2647092A1 Indole derivatives as inhibitors of the soluble adenylate cyclase |
| 09/27/2007 | CA2647089A1 Association of oleaginous substance with a mixture of at least two cyclodextrins |
| 09/27/2007 | CA2647024A1 Substituted tetrahydroisoquinoline compounds, their preparation and use in medicaments |
| 09/27/2007 | CA2647020A1 Conjugated lipid derivatives |
| 09/27/2007 | CA2646977A1 6,7,8,9 -tetrahydro-5h-pyrimido[4,5-d]azepin-4-yl]-amine derivatives as modulators of trpvl for the treatment of pain |
| 09/27/2007 | CA2646971A1 Paclitaxel combination |
| 09/27/2007 | CA2646969A1 Treatment or prevention of scarring, capsular contractures and/or hyperpigmentation using leukotriene receptor antagonist and vitamin e |
| 09/27/2007 | CA2646958A1 Heterocyclic substituted pyridine compounds with cxcr3 antagonist activity |
| 09/27/2007 | CA2646896A1 Benzimidazoles which have activity at m1 receptor and their uses in medicine |
| 09/27/2007 | CA2646891A1 Immunopotentiating compounds |
| 09/27/2007 | CA2646627A1 Rosiglitazone hydrochloride hemihydrate |
| 09/27/2007 | CA2646594A1 Soluble adenylate cyclase inhibitors |
| 09/27/2007 | CA2646588A1 Adamantane derivatives for the treatment of the metabolic syndrome |
| 09/27/2007 | CA2646585A1 Compounds which potentiate ampa receptor and uses thereof in medicine |
| 09/27/2007 | CA2646539A1 Imidazoquinoxaline compounds as immunomodulators |
| 09/27/2007 | CA2646469A1 S1p receptor modulating compounds |
| 09/27/2007 | CA2646463A1 4-(pyrrolopyridinyl)pyrimidinyl-2-amine derivatives |
| 09/27/2007 | CA2646460A1 Treatment of poultry for reducing the feed conversion rate or for reducing the incidence of ascites |
| 09/27/2007 | CA2646379A1 Method of treatment or prophylaxis inflammatory pain |
| 09/27/2007 | CA2646334A1 Bisphosphonate compounds and methods |
| 09/27/2007 | CA2646333A1 Method of preventing and treating hepatic disease using a2b adenosine receptor antagonists |